Target intelligence / Profile preview

Cytotoxic CD8-positive alpha-beta T cell (CD8+ αβ T cell (or CTL, cytotoxic T lymphocyte))

Target
CD8+ αβ T cell (or CTL, cytotoxic T lymphocyte)
Molecular classification
Immune cell
01

Overview

A cytotoxic CD8-positive alpha-beta T cell is an immune effector cell that plays a central role in adaptive immunity. These cells express both the alpha-beta form of the T-cell receptor and the co-receptor protein CD8 on their surface. They are primarily responsible for recognizing and eliminating host cells that have been infected by intracellular pathogens such as viruses or transformed by cancer. Upon activation through interaction with antigen-presenting cells displaying peptide antigens bound to major histocompatibility complex class I molecules, cytotoxic CD8-positive alpha-beta T cells release cytotoxic granules containing granzymes and perforin, inducing apoptosis in their targets. Their development occurs in the thymus through positive and negative selection processes ensuring self-tolerance while maintaining reactivity against foreign antigens[1][2][3]. This description highlights that "Cytotoxic CD8-positive alpha-beta T cell" refers to an entire immune effector population rather than an individual molecule or receptor.

Other names
Cytotoxic CD8+ αβ T lymphocyteCytotoxic CD8+ αβ T-cellCTL (cytotoxic T lymphocyte) when referring to effector function
02

Biological functions

Immune response: detection and elimination of infected or malignant cellsCell death: induction of apoptosis in target cells via granzymes and perforin
03

Disease associations

Cancer: tumor surveillance and destructionInfection: defense against intracellular pathogens such as viruses

Beyond the preview

Go deeper on Cytotoxic CD8-positive alpha-beta T cell (CD8+ αβ T cell (or CTL, cytotoxic T lymphocyte)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytotoxic CD8-positive alpha-beta T cell (CD8+ αβ T cell (or CTL, cytotoxic T lymphocyte)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call